Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05483933 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
A Phase 1 study, sponsored by Shattuck Labs.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT05483933: Completed Phase 1 study, sponsored by Shattuck Labs.
NCT05483933 is a Phase 1 study that has completed, run by Shattuck Labs. The registered enrollment target is 86 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05483933, a Phase 1 study, has completed, sponsored by Shattuck Labs.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in this study.
Primary Outcome
Number of participants with treatment emergent adverse events from dose escalation and expansion cohorts
Interventions
- DRUG Pegylated Liposomal Doxorubicin + SL-172154
- DRUG Mirvetuximab + SL-172154
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-08-18 |
| Est. Completion | 2025-02-07 |
| Phase | Phase 1 |
What the finished NCT05483933 record still lists
NCT05483933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher).
The record links to 0 conditions, and to 2 interventions - of which Pegylated Liposomal Doxorubicin + SL-172154 is the first listed.
NCT05483933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05483933 about?
NCT05483933 is a clinical study titled "Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers". SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in this...
What is the current status of trial NCT05483933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2022-08-18. Estimated completion is 2025-02-07.
What interventions are being tested in trial NCT05483933?
The interventions under investigation include: Pegylated Liposomal Doxorubicin + SL-172154 (DRUG), Mirvetuximab + SL-172154 (DRUG).
Who is sponsoring clinical trial NCT05483933?
This trial is sponsored by Shattuck Labs, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05483933's enrollment target sits among peer trials
86 652nd of 2000 higher than 1,345 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI